ArticleHeliyon2017
Epidermal growth factor prevents
Article in Heliyon, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Association between Periodontal Disease and Cognitive Impairment in Adults.International journal of environmental research and public health · 2023Pooled it
- Viral Induced Oxidative and Inflammatory Response in Alzheimer's Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach.Current neuropharmacology · 2019Pooled it
- Development of Plasma Protein Classification Models for Alzheimer's Disease Using Multiple Machine Learning Approaches.International journal of molecular sciences · 2025Article
- Compensatory retinal blood flow enhancement in cognitively normal ApoE ε4 carriers.Scientific reports · 2025Article
- Deficiency in N-cadherin-Akt3 signaling impairs the blood-brain barrier.Cell reports · 2025Article
- Apolipoprotein E polymorphisms and female fertility in a transgenic mouse model of Alzheimer's disease.Scientific reports · 2024Article
- Estradiol improves behavior in FAD transgenic mice that expressFrontiers in endocrinology · 2024Article
- APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice.Journal of Alzheimer's disease : JAD · 2024Article
- Alzheimer's disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles.Frontiers in neuroscience · 2024Review
- A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.Alzheimer's research & therapy · 2023Article
- A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice.Alzheimer's research & therapy · 2023Article
- Endothelial CellArteriosclerosis, thrombosis, and vascular biology · 2023Article
- Role of mucin glycosylation in the gut microbiota-brain axis of core 3 O-glycan deficient mice.Scientific reports · 2023Article
- Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Article
- Regulation of blood-brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide.Microbiome · 2021Article
- LPC-DHA/EPA-Enriched Diets Increase Brain DHA and Modulate Behavior in Mice That Express HumanFrontiers in neuroscience · 2021Article
- Autocrine Effects of Brain Endothelial Cell-Produced Human Apolipoprotein E on Metabolism and InflammationFrontiers in cell and developmental biology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrovascular dysfunction is re-emerging as a major component of aging, and may contribute to the risk of developing Alzheimer's disease (AD). Two important risk factors for cerebrovascular dysfunction are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.